Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Optimizing the use of prescription drugs in Canada through the Common Drug Review.

Literature DB >> 18268271

Optimizing the use of prescription drugs in Canada through the Common Drug Review.

Mike Tierney¹, Braden Manns.

Abstract

Mesh：

Year: 2008 PMID： 18268271 PMCID： PMC2228339 DOI： 10.1503/cmaj.070713

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

4 in total

Review 1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors:
Journal: Clin Pharmacol Ther Date: 2001-03 Impact factor: 6.875

2. Surrogate endpoints and FDA's accelerated approval process.

Authors: Thomas R Fleming
Journal: Health Aff (Millwood) Date: 2005 Jan-Feb Impact factor: 6.301

3. Surrogate markers in clinical studies: problems solved or created?

Authors: Braden Manns; William F Owen; Wolfgang C Winkelmayer; P J Devereaux; Marcello Tonelli
Journal: Am J Kidney Dis Date: 2006-07 Impact factor: 8.860

4. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.

Authors: Steven G Morgan; Meghan McMahon; Craig Mitton; Elizabeth Roughead; Ray Kirk; Panos Kanavos; Devidas Menon
Journal: Health Aff (Millwood) Date: 2006 Mar-Apr Impact factor: 6.301

4 in total

21 in total

1. A comparison of drug coverage in alberta before and after the introduction of the national common drug review process.

Authors: John-Michael Gamble; Dean T Eurich; Jeffrey A Johnson
Journal: Healthc Policy Date: 2010-11

2. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review.

Authors: John-Michael Gamble; Daniala L Weir; Jeffrey A Johnson; Dean T Eurich
Journal: CMAJ Date: 2011-10-24 Impact factor: 8.262

3. Access to cancer drugs in Canada: looking beyond coverage decisions.

Authors: Roger Chafe; Anthony Culyer; Mark Dobrow; Peter C Coyte; Carol Sawka; Susan O'Reilly; Kara Laing; Maureen Trudeau; Sharon Smith; Jeffrey S Hoch; Steve Morgan; Stuart Peacock; Rick Abbott; Terrence Sullivan
Journal: Healthc Policy Date: 2011-02

10. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.

Authors: Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Donna Rindress; Jean-Pierre Grégoire; Cheri Deal
Journal: Cost Eff Resour Alloc Date: 2010-04-08

Optimizing the use of prescription drugs in Canada through the Common Drug Review.

Review 1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

2. Surrogate endpoints and FDA's accelerated approval process.

3. Surrogate markers in clinical studies: problems solved or created?

4. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.

1. A comparison of drug coverage in alberta before and after the introduction of the national common drug review process.

2. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review.

3. Access to cancer drugs in Canada: looking beyond coverage decisions.

4. Common Drug Review recommendations: an evidence base for expectations?

Review 5. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Review 6. Moving from opacity to transparency in pharmaceutical policy.

7. The power of "principles" in a national pharmaceuticals strategy.

8. Access without Appropriateness: Chicken Little in Charge?

9. Cost shifting and timeliness of drug formulary decisions in atlantic Canada.

10. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.